ArticleHealth economics review2024

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China.

Shitong Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.